abstract |
The present invention belongs to the technical field of biopharmaceuticals, and provides an improved anti-VEGFR-2 monoclonal antibody and its application. In the present invention, a new phage display antibody library is designed by computer-aided simulation design, and screened multiple times to obtain an improved anti-VEGFR-2 monoclonal antibody. Both the affinity and the biological activity of the antibody are higher than those of the original antibody, which can effectively inhibit the binding of VEGFR-2 and its ligand VEGFR outside the body, and diseases caused by neonatal blood vessels such as tumors and macular degeneration Used for the treatment of |